BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day.

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Healthy returns: Japan’s assault on old-age di ...

Biogen and City Therapeutics are to partner for the development of new RNA interference (RNAi) therapies. Leveraging ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

BDS has performed consultancies for Roche, Eisai, EQTpartners, Remynd, Tactile, Earlybird, Sironax, Montis, and Abyssinia; and is a shareholder of Muna Tx. CH collaborates with Denali Therapeutics and ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, ...

The test will initially be available at about 50 American research institutes and hospitals that specialise in Alzheimer’s ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

Investing.com -- Shares in BioArctic AB (ST: BIOAb) rose more than 4% on Wednesday after the company posted ...

Medicare will cover 80% of Leqembi’s $26,500 cost, The New York Times says, but patients could still shoulder thousands of dollars in co-payments. The New York Times: FDA Makes Alzheimer’s Drug ...

The test potentially makes it easier to find and treat patients with the memory-robbing disease. Read more at ...